Fujifilm Announces the Commercialization of Two Novel Endoscopic Imaging Technologies, CAD EYE® and SCALE EYE® at the Digestive Disease Week (DDW®) 2024 Conference
May 16 2024 - 12:52PM
FUJIFILM Healthcare Americas Corporation, a leading provider of
endoscopic imaging and endosurgical solutions, today announced the
commercialization of its two novel endoscopic imaging technologies,
CAD EYE®, the company’s AI detection system for endoscopic imaging
which enables real-time detection of colonic mucosal lesions during
colonoscopy procedures, and SCALE EYE®, a first-of-its-kind imaging
technology for measuring colonic lesions. Both technologies will be
demonstrated at the 2024 Digestive Disease Week (DDW®) annual
conference and exhibition in booth 2829, held May 18-21 in
Washington, DC.
“Our vision has been laser focused on delivering the best
possible endoscopic imaging solutions to meet our customers’
growing needs. Knowing how critical it is for GI physicians to
accurately visualize and measure lesions during colonoscopy, we are
eager to launch CAD EYE and SCALE EYE,” says Tai Fujita, vice
president, Endoscopy Division, FUJIFILM Healthcare Americas
Corporation. “Our team looks forward to demonstrating how
Fujifilm’s state-of-the-art endoscopic technologies are offering
outstanding levels of image clarity and performance to industry
experts and physicians at the upcoming DDW.”
Since receiving 510(k) clearance for CAD EYE in March, the
technology has been installed at five clinical sites in the U.S.,
including ASCs, community hospitals, and academic medical
centers.
“This system expansion from Fujifilm represents an exciting step
forward at a time when quality in colonoscopy is a critical focus
across the GI community,” said Jason B. Samarasena, MD,
gastroenterologist with UCI Health. “Leveraging AI for polyp
detection support with CAD EYE, along with the introduction of
SCALE EYE, a novel real-time polyp measurement solution – both
seamlessly integrated with the innovative ELUXEO platform -
Fujifilm is helping to address several key challenges and working
alongside endoscopists to elevate quality standards in
colonoscopy.”
Two recognized industry leaders will present real-world
application as well as clinical findings on Fujifilm’s novel CAD
EYE in booth #2829 at the upcoming DDW conference, including:
New Paradigm for Colonoscopy 2024: Sunday, May 19
11:30am – 12:30 pm ET
Alessandro Repici, MD, Professor of Gastroenterology, Chairman
Department of Gastroenterology, Humanitas University &
Humanitas Research Hospital will present on CAD EYE colon polyp
detection in practice, and how the Fujifilm ELUXEO system delivers
a comprehensive set of innovative solutions for endoscopy.
CAD EYE: US Clinical Trial Data and Why It's Compelling:
Monday, May 20 11:30am – 12:30 pm ET
Sravanthi Parasa, MD, FASGE, Gastroenterology, Swedish Medical
Center, Clinical Researcher in Gastroenterology & AI in
Medicine will present clinical findings on CAD EYE advances
in colorectal cancer diagnosis, including 17% higher adenoma per
colonoscopy (APC) compared to high-definition conventional
colonoscopy without AI assistance, the ability to detect colorectal
neoplastic lesions at a level comparable to that of an expert and
superior to that of a beginner 1 , and more.
To book your demonstration with Fujifilm at DDW 2024, click
here.
1. Neumann H et al. 2021. PLoS One 16(8):e0255955,
PMID: 34437563.
About Fujifilm
FUJIFILM Healthcare Americas Corporation is a comprehensive
healthcare company that has an extensive range of technology and
expertise in the detection, diagnosis and treatment of diseases.
Fujifilm’s innovative medical imaging portfolio includes solutions
for digital radiography, mammography, CT, MRI, ultrasound,
gastroenterology, pulmonology, endosurgery, and minimally invasive
surgery. The award-winning Synapse® Enterprise Imaging portfolio
provides healthcare professionals with the cross-departmental
imaging and data access needed to deliver a complete patient
record. Fujifilm’s AI initiative, REiLI®, combines Fujifilm’s rich
image-processing heritage with cutting-edge innovations to inspire
clinical confidence and combat burnout. The In-Vitro Diagnostic
portfolio provides the gold standard of molecular based immunoassay
technology for liver surveillance, cutting edge clinical diagnostic
chemicals for leading laboratories and diagnostic chemicals for OEM
white labelling products. The company is headquartered in
Lexington, Massachusetts. Click here for more information.
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of
knowledge and proprietary core technologies to deliver “Value from
Innovation” in our products and services in the business segments
of healthcare, materials, business innovation, and imaging. Our
relentless pursuit of innovation is focused on providing social
value and enhancing the lives of people worldwide. Fujifilm is
committed to responsible environmental stewardship and good
corporate citizenship. For more information about Fujifilm’s
Sustainable Value Plan 2030, click here. For the year ended March
31, 2023, the company had global revenues of approximately 2.9
trillion yen (21 billion USD at an exchange rate of 134
yen/dollar). For more information, please
visit: www.fujifilmholdings.com.
FUJIFILM, CAD EYE, SCALE EYE, ELUXEO, SYNAPSE, REILI and VALUE
FROM INNOVATION are trademarks and registered trademarks of
FUJIFILM Corporation and its affiliates. DDW is a registered
trademark of DDW, LLC. All other trademarks are the property of
their respective owners.
Marissa Confredo
FUJIFILM Holdings America Corporation
914-789-8526
marissa.confredo@fujifilm.com